Sichuan Biokin Pharmaceutical Co Ltd banner
S

Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506

Watchlist Manager
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Watchlist
Price: 273 CNY -4.05% Market Closed
Market Cap: ¥112.7B

EV/FCFF

-43.1
Current
23%
Cheaper
vs 3-y average of -56

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
-43.1
=
Enterprise Value
¥116.6B
/
Free Cash Flow to Firm
¥-2.5B

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
-43.1
=
Enterprise Value
¥116.6B
/
Free Cash Flow to Firm
¥-2.5B

Valuation Scenarios

Sichuan Biokin Pharmaceutical Co Ltd is trading above its industry average

If EV/FCFF returns to its Industry Average (30.7), the stock would be worth ¥-194.55 (171% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-171%
Maximum Upside
No Upside Scenarios
Average Downside
169%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple -43.1 ¥273
0%
Industry Average 30.7 ¥-194.55
-171%
Country Average 28.8 ¥-182.52
-167%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close
Market Cap EV/FCFF P/E
CN
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
112.7B CNY -43.1 -132.2
US
Eli Lilly and Co
NYSE:LLY
804.2B USD 140.4 39
US
Johnson & Johnson
NYSE:JNJ
547.4B USD 29.1 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 26.4 20.1
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP 34.8 27.5
CH
Novartis AG
SIX:NOVN
220.1B CHF 19 19.5
US
Merck & Co Inc
NYSE:MRK
274.6B USD 24.8 15
IE
Endo International PLC
LSE:0Y5F
244.4B USD 1 486.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 42.2 11.1
US
Pfizer Inc
NYSE:PFE
149.3B USD 21.8 19.2
US
Bristol-Myers Squibb Co
NYSE:BMY
115.9B USD 11.6 16.4
P/E Multiple
Earnings Growth PEG
CN
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Average P/E: 21.5
Negative Multiple: -132.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39
32%
1.2
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.5
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.2
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.4
16%
1

Market Distribution

Lower than 100% of companies in China
Percentile
0th
Based on 4 731 companies
0th percentile
-43.1
Low
0 — 14.5
Typical Range
14.5 — 57
High
57 —
Distribution Statistics
China
Min 0
30th Percentile 14.5
Median 28.8
70th Percentile 57
Max 307 555.7

Sichuan Biokin Pharmaceutical Co Ltd
Glance View

Market Cap
112.7B CNY
Industry
Pharmaceuticals

Sichuan Biokin Pharmaceutical Co Ltd, nestled in the thriving economic landscape of China, is a dynamic force in the pharmaceutical industry. The company has carved a niche for itself by specializing in the production and commercialization of generic and proprietary drugs. Founded on the principles of innovation and accessibility, Biokin has dedicated its resources to the development of a wide range of pharmacological solutions that address both chronic and acute health conditions. Its state-of-the-art manufacturing facilities are complemented by rigorous research and development wings, where scientists and pharmacists collaborate meticulously to forge products that meet the stringent standards of efficacy and safety. At the heart of Sichuan Biokin's business model lies a commitment to affordability and quality, a combination that has enabled it to secure a significant share of the domestic pharmaceutical market. The company capitalizes on the economies of scale, leveraging its expansive production capabilities to reduce costs and enhance profit margins. By strategically aligning with healthcare providers and distributors, Biokin ensures its products efficiently reach hospitals, clinics, and pharmacies across the nation. This extensive distribution network not only enhances accessibility for patients but also cements Biokin’s reputation as a reliable pharmaceutical partner. Meanwhile, its growing portfolio of consumer healthcare products, alongside ongoing investments in biosimilars and more complex drug formulations, positions Biokin to thrive in the ever-evolving global healthcare arena.

Intrinsic Value
24.65 CNY
Overvaluation 91%
Intrinsic Value
Price ¥273
S
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett